论文部分内容阅读
目的观察托拉塞米治疗老年慢性心力衰竭(CHF)患者的临床效果及安全性。方法将88例老年CHF患者随机分为观察组和对照组,每组44例。对照组采用常规治疗,观察组在对照组基础上采用托拉塞米治疗,治疗周期7 d。观察2组治疗前后血钾、血钠、血肌酐(Scr)及24 h尿量变化情况;观察2组治疗前后NYHA分级及临床疗效、不良反应发生情况。结果观察组总有效率为72.73%,高于对照组的52.27%(P<0.05);治疗后,2组24 h尿量较治疗前均升高,观察组较对照组升高明显(P均<0.05);观察组NYHA分级Ⅰ~Ⅱ级率为47.73%,高于对照组的22.73%(P<0.05)。治疗后,2组患者均未发生严重的不良反应。结论托拉塞米治疗CHF疗效显著,能明显利尿并促进患者心功能恢复,且安全性较好。
Objective To observe the clinical efficacy and safety of torsemide in elderly patients with chronic heart failure (CHF). Methods 88 elderly CHF patients were randomly divided into observation group and control group, 44 cases in each group. The control group was treated by conventional therapy. The observation group was treated with torsemide on the basis of the control group, and the treatment period was 7 days. The changes of serum potassium, serum sodium, serum creatinine (Scr) and 24 h urine before and after treatment were observed. The NYHA classification, clinical efficacy and adverse reactions before and after treatment were observed. Results The total effective rate in the observation group was 72.73%, which was higher than that in the control group (52.27%, P <0.05). After 24 hours of treatment, the urine output of 24 hours group was significantly higher than that of the control group <0.05). The NYHA grade Ⅰ ~ Ⅱ grade in the observation group was 47.73%, which was higher than that in the control group (22.73%, P <0.05). After treatment, no serious adverse reactions occurred in both groups. Conclusion Torasemide treatment of CHF significant effect, can significantly diuretic and promote cardiac function recovery, and safety is better.